1. Academic Validation
  2. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite

  • Science. 2005 Nov 4;310(5749):850-5. doi: 10.1126/science.1117634.
Michael Platten 1 Peggy P Ho Sawsan Youssef Paulo Fontoura Hideki Garren Eun Mi Hur Rohit Gupta Lowen Y Lee Brian A Kidd William H Robinson Raymond A Sobel Michael L Selley Lawrence Steinman
Affiliations

Affiliation

  • 1 Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA 94305, USA. michael.platten@uni-tuebingen.de
Abstract

Local catabolism of the amino acid tryptophan (Trp) by indoleamine 2,3-dioxygenase (IDO) is considered an important mechanism of regulating T cell immunity. We show that IDO transcription was increased when myelin-specific T cells were stimulated with tolerogenic altered self-peptides. Catabolites of Trp suppressed proliferation of myelin-specific T cells and inhibited production of proinflammatory T helper-1 (T(H)1) cytokines. N-(3,4,-Dimethoxycinnamoyl) anthranilic acid (3,4-DAA), an orally active synthetic derivative of the Trp metabolite anthranilic acid, reversed paralysis in mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis (MS). Trp catabolites and their derivatives offer a new strategy for treating T(H)1-mediated autoimmune diseases such as MS.

Figures
Products